

Surveys and Anatomic Pathology Education Programs

Performance Improvement Program in Surgical Pathology PIP/PIPW-D 2022

Participant Summary

This document is available online in e-LAB Solutions Suite.

© 2022 College of American Pathologists. The CAP does not permit reproduction of any substantial portion of the material in this Report without its written authorization. The CAP hereby authorizes participants in the program to use the material in this Report solely for educational purposes within their own institutions. The CAP prohibits use of the material in the Report — and any unauthorized use of the CAP's name or logo — in connection with promotional efforts by marketers of laboratory equipment, reagents, materials, or services. Data from this program do not necessarily indicate the superiority or inferiority of instruments, reagents, or other materials used by participating laboratories. Use of these data to suggest such superiority or inferiority may be deceptive and misleading. The CAP will take all steps open to it under the law to prevent unauthorized reproduction of substantial portions of the material in this Report, deceptive use of any such material, and any unauthorized use of the CAP's name or logo in connection with promotional efforts by marketers of laboratory equipment, reagents, materials, or services.

2022 PIP/PIPW-D **PARTICIPANT SUMMARY**

Program Update

This report summarizes the diagnostic responses for set D of the 2022 Performance Improvement Program in Surgical Pathology (PIP & PIPW).

A tabulation of the responses to the supplementary questions is not included since these are intended for educational purposes only.

SURGICAL PATHOLOGY COMMITTEE

Aaron Auerbach, MD FCAP, Chair Raul Gonzalez, MD FCAP, Vice-Chair

Oyedele A. Adeyi, MBBS, FCAP Nadine S. Aguilera, MD, FCAP Vijayalakshmi Ananthanarayanan, MD, MBBS FCAP Xiaoyin Jiang, MD, FCAP Phyu P. Aung, MD, PhD, FCAP Lamé Balikani, MD, MPH Deborah Ann Belchis, MD, FCAP Miriam Conces, MD, FCAP Kossivi Dantey, MD, FCAP Megan B. Fitzpatrick, MD, FCAP Juan C. Hernandez-Prera, MD, FCAP

Mojgan Hosseini, MD, FCAP Taylor McAneney Jenkins, MD, FCAP Mitra Mehrad, MD, FCAP Vinita Parkash, MD, FCAP Anwar Sultana Sabiha Raza, MD, FCAP Nicole D. Riddle, MD, FCAP Lauren Schwartz, MD, FCAP Robert A. Schwartz, MD, FCAP Steven S. Shen, MD, PhD, FCAP Sabrina C. Sopha, MD, FCAP

The CAP Surgical Pathology Committee relies on the donations of tissue blocks to sustain the PIP glass slide Proficiency Testing Survey and greatly appreciates and thanks all who have donated tissue blocks for use in the PIP Surveys. At the end of each year, case donors who submitted cases during the year will be listed in the PIP-D PSR by individual or institution. Due to patient confidentiality, individual cases will not be listed by institution.

The CAP Surgical Pathology Committee would like to thank the following individual or institution for its generous donations of tissue blocks in 2022 for use in PIP Proficiency Testing Surveys:

Neil Alouch, MD
Kossivi Dantey, MD
Christopher Flynn, MD
Mariza de Peralta-Venturina, MD
Nicole Riddle, MD
Robert A. Schwartz ,MD
Sabrina Sopha, MD

	Diagno: (5798) O	sis esteopetrosis				
_		1	PIP Partio	cipants	PIPW Part	icipants
2-3	Code	Diagnosis	No.	%	No.	%
# 2022-31					40	
	2757	Low-grade central osteosarcoma	14	0.2	12	2.8
Case	2952	Myositis ossificans	28	0.5	31	7.5
ပိ	5798	Osteopetrosis	5634	97.8	312	72.2
	1501	Paget disease	80	1.4	74	17.1
	5580	Primary myelofibrosis	4	0.1	2	0.4

	Diagno : (5799) N	s is odular hyperplasia				
2			PIP Particip	oants	PIPW Partio	ipants
22-3	Code	Diagnosis	No.	%	No.	%
# 2022-32	1935	Follicular adenoma	22	0.4	14	3.3
Case	1176	Follicular carcinoma, widely invasive	2	<0.1	7	1.6
ပိ	1678	Graves disease	14	0.2	17	4.1
	5588	Hashimoto thyroiditis with nodular change	1	<0.1	6	1.4
	5799	Nodular hyperplasia	5718	99.2	377	89.6

	Diagno					
	(5801) C	Cardiac hereditary transthyretin amyloidosis				<u> </u>
			PIP Partici	oants	PIPW Parti	cipants
-33	Code	Diagnosis	No.	%	No.	%
# 2022-33						
# 2	3032	Cardiac hemochromatosis	9	0.2	3	0.7
se	5800	Cardiac light chain deposition disease	37	0.6	11	2.6
Case	5801	Cardiac hereditary transthyretin amyloidosis	5693	98.9	386	93.0
	5802	Fabry disease-related cardiomyopathy	5	0.1	4	0.9
	2543	Hypertrophic cardiomyopathy	13	0.2	12	2.8

	Diagno	sis				
	(5553) D	riffuse epithelioid mesothelioma				
4			PIP Particip	ants	PIPW Partio	cipants
2-3	Code	Diagnosis	No.	%	No.	%
# 2022	5553	Diffuse epithelioid mesothelioma	 5749	99.6	396	98.5
Case	5803	Lung adenocarcinoma	3	0.1	1	0.2
ပိ	5804	Lung squamous cell carcinoma	2	<0.1	2	0.4
	1674	Metastatic melanoma	1	<0.1	1	0.2
	5805	Reactive mesothelial hyperplasia	2	(0.1	3	0.7

	Diagno : (2068) S	s is ynovial sarcoma				
	(====) =		PIP Partici		PIPW Partio	•
-35	Code	Diagnosis	No.	%	No.	%
Case # 2022-35	2743	Clear cell sarcoma	15	0.3	9	2.2
#	1901	Gastrointestinal stromal tumor	1	<0.1	1	0.2
ase	5562	Malignant peripheral nerve sheath tumor	4	0.1	3	0.7
ပ	1649	Solitary fibrous tumor	14	0.2	8	2.0
	5806	Spindle cell/sclerosing rhabdomyosarcoma	7	0.1	2	0.5
	2068	Synovial sarcoma	5719	99.2	377	94.4

	Diagno (1665) C	s is lear cell renal cell carcinoma				
9			PIP Particip	oants	PIPW Partio	cipants
2-3	Code	Diagnosis	No.	%	No.	%
, # 2022-36	1984	Chromophobe renal cell carcinoma	31	0.5	7	1.8
Case	2632	Clear cell papillary renal cell carcinoma	231	4.0	18	4.5
ပ	1665	Clear cell renal cell carcinoma	5482	95.2	365	92.7
	2605	Epithelioid angiomyolipoma	9	0.2	8	2.0
	1797	Papillary renal cell carcinoma	6	0.1	0	0.0

	Diagno	sis				
	(1736) V					
			PIP Partici	oants	PIPW Participants	
Case # 2022-37	Code	Diagnosis	No.	%	No.	%
022						
# 2	2414	Acinar cell carcinoma	14	0.2	7	1.8
Se	1305	Pancreatic ductal adenocarcinoma	2	<0.1	1	0.2
Cas	1539	Poorly differentiated neuroendocrine carcinoma	80	1.4	20	5.1
	2300	Solid pseudopapillary neoplasm	14	0.2	10	2.5
	1736	Well-differentiated neuroendocrine tumor	5647	98.1	358	90.4

	Diagnos	sis				
	(5810) C	ryptogenic cirrhosis				
			PIP Partici	pants	PIPW Part	icipants
38	Code	Diagnosis	No.	%	No.	%
22-	'					
20	5807	Alcoholic-type cirrhosis	13	0.2	10	2.5
Case # 2022-38	5808	Cirrhosis secondary to primary biliary cholangitis	54	0.9	44	11.1
Ö	5809	Cirrhosis secondary to alpha-1 antitrypsin deficiency	31	0.5	25	6.3
	5810	Cryptogenic cirrhosis	5650	98.1	310	79.0
	5811	Viral hepatitis C-induced cirrhosis	10	0.2	5	1.1

	Diagnos	sis				
	(5547) Py	yloric gland adenoma				
6			PIP Particip	ants	PIPW Partic	ipants
2-3	Code	Diagnosis	No.	%	No.	%
202						
	5812	Chronic peptic duodenitis	4	0.1	3	8.0
3Se	1902	Hyperplastic polyps	12	0.2	17	4.4
ပိ	5813	Intestinal-type adenoma	65	1.1	70	18.0
	5814	Oxyntic gland adenoma	55	1.0	23	5.8
	5547	Pyloric gland adenoma	5607	97.6	277	71.0
Case # 2022-39	5812 1902 5813 5814	Chronic peptic duodenitis Hyperplastic polyps Intestinal-type adenoma Oxyntic gland adenoma	4 12 65 55	0.1 0.2 1.1 1.0	3 17 70 23	

	Diagnos	sis				
	(5556) F	lorid follicular hyperplasia				
			PIP Participa	nts	PIPW Partio	cipants
0	Code	Diagnosis	No.	%	No.	%
# 2022-40	•	-				
:02	5815	Castleman lymphadenopathy	76	1.3	54	13.9
# 2	5556	Florid follicular hyperplasia	5423	94.4	205	52.7
Case	1686	Follicular lymphoma, grade 1-2 (low grade), follicular pattern	18	0.3	8	2.1
	5816	lgG4-related lymphadenopathy	3	0.1	4	1.0
	2966	Progressive transformation of germinal centers	210	3.7	114	29.3
	5817	Toxoplasmosis lymphadenopathy	14	0.2	4	1.0

